Nephrocare Health IPO: Nephrocare Health IPO will open for subscription on December 10, 2025, and close on December 12, 2025, with the company aiming to raise ₹871.05 crore. The Nephrocare Health IPO price band has been set at ₹438 to ₹460 per share.
The issue comprises a fresh issue of 0.77 crore shares aggregating to ₹353.40 crore and an offer for sale of 1.13 crore shares aggregating to ₹517.64 crore.
From the fresh issue proceeds, the company intends to allocate ₹129.1 crore for setting up new dialysis clinics in India, ₹136 crore for debt repayment, and the balance toward general corporate purposes.
The allotment for the Nephrocare Health IPO is expected to be finalized on December 15, 2025. The shares will list on the BSE and NSE, with a tentative listing date of December 17, 2025. The lot size for an application is 32 shares, requiring a minimum retail investment of ₹14,720 (32 shares) at the upper price band.
NephroPlus is India’s largest dialysis network, operating clinics across 288 cities in 21 states and 4 union territories as of September 2025. Of these centres, 77% are located in tier II and tier III towns and cities.
Nephrocare Health IPO GMP
Investor sentiment toward the IPO was muted, as Nephrocare Health’ grey market premium (GMP) was ₹0 on December 8. This suggested that the stock was likely to debut at ₹460, same as IPO price.
‘Grey market premium’ indicates investors’ readiness to pay more than the issue price.
Top 10 Key Risks Investors Must Know Before Investing
1. Heavy dependence on captive clinics: A significant share of Nephrocare’s revenue comes from captive clinics operating inside private hospitals—36.51% (H1 FY26), 43.30% (FY25), 51.96% (FY24), and 62.23% (FY23). If hospitals terminate these agreements, fail to renew them, or alter contract terms unfavourably, the company could face a sharp revenue decline.
2. High reliance on PPP contracts: Nephrocare earns a substantial portion of its revenue from PPP (public–private partnership) clinics: 30.96% (H1 FY26), 32.62% (FY25), 29.24% (FY24), 22.39% (FY23). Winning and renewing these tenders is highly competitive and uncertain. Any policy changes, cancellations, pricing revisions, or delays in tendering can hurt future revenue.
3. Sector Risk: The dialysis sector in India is deeply influenced by government health schemes such as PM-JAY, state-level insurance programs, and public hospital reimbursement models. The RHP notes that pricing under these schemes is often fixed and subject to periodic review, leaving limited room for providers to pass on rising costs related to staffing, consumables, equipment, and compliance. Any downward revision of reimbursement rates, delays in payments, changes in eligibility criteria, or budgetary constraints could materially impact margins.
4. Shortage of skilled healthcare professionals: Nephrocare depends heavily on nephrologists, dialysis technicians, and trained nurses. Industry-wide shortages mean the company faces retention challenges and rising talent costs. Any inability to recruit or keep qualified staff could disrupt operations, impair quality of care, reduce clinic capacity, and slow expansion.
5. Expansion risks in new cities: The company may face difficulties expanding in current geographies or entering new countries such as the Philippines, Uzbekistan, and Nepal. Challenges include regulatory approvals, licensing delays, cultural and operational misalignment, infrastructure gaps, and lack of local expertise. Failure to scale successfully could weaken long-term growth prospects. International regulatory non-compliance could also expose the company to penalties or operational shutdowns.
6. Business interruption risks across clinics: Dialysis clinics are vulnerable to equipment failures, fires, power outages, natural disasters, pandemics, vandalism, and regulatory closures. Events like the COVID-19 period—where several partner hospitals converted into COVID-dedicated facilities—forced temporary shutdowns. Such disruptions directly reduce revenue and can damage patient trust. Insurance may not fully cover losses, making this a material operational and financial risk.
7. Inadequate insurance coverage: Although Nephrocare holds insurance policies covering certain operational risks—medical indemnity, D&O liability, fire and burglary, business insurance, and accident coverage—these policies include standard exclusions and coverage limits. The RHP warns that insurance may not fully cover losses arising from equipment failure, fires, natural disasters, vandalism, patient claims, cyber incidents, operational interruptions, or legal liabilities. Some captive clinics rely on hospitals for insurance coverage, adding further variability. Any uninsured or under-insured event could significantly affect financial performance, cash flows, and operations.
8. Regulatory and compliance risks: Dialysis centres must comply with numerous safety, health, environmental, and biomedical waste regulations. Non-compliance can result in fines, license revocation, operational shutdowns, or legal proceedings. The company operates across multiple Indian states and foreign jurisdictions, increasing exposure to regulatory changes. Even routine failures in documentation or wastewater management could lead to significant consequences.
9. Risks from equipment failure: The company relies on complex medical equipment such as reverse osmosis systems and dialysis machines. Breakdowns, faulty maintenance, electrical failures, fires, or tampering could halt operations and harm patients. While no major incidents occurred recently, the company notes that any such event would severely impact earnings, reputation, and patient safety. Insurance coverage—especially for captive clinics—may be inadequate.
10. Financial Risks: Nephrocare requires significant working capital and relies on external financing. Any inability to secure favourable loans could restrict growth or raise interest costs. A downgrade in credit rating would also inflate borrowing costs. Additionally, as the company expands internationally, exposure to interest rate volatility and foreign exchange movements may affect profitability and cash flows.
